A generic drug manufacturer entering the Kenyan market is the practical starting point for anyone facing this situation, and it is where this article begins: registration is not a single event but two separate approvals running in parallel, one for the product and one for the premises that make it, and both sit with the Pharmacy and Poisons Board. Manufacturers who plan for only one of these tend to discover the gap at the worst possible moment, once production capacity is already committed.
Market Authorisation for Generic Medicines
Before a generic medicine can be sold in Kenya, it needs its own Market Authorisation from the PPB, regardless of whether the same molecule is already registered and marketed by another manufacturer. The Board’s marketing authorisation process for medicines containing synthetic or semi-synthetic active pharmaceutical ingredients requires a technical dossier covering product composition, safety data, manufacturing practices, and labelling, with the specific data requirements assessed case by case depending on the product. For a generic specifically, the core of the application is demonstrating that the product is equivalent in quality, safety, and therapeutic effect to an already-registered reference product, rather than repeating the full clinical development programme the original innovator product went through.
This is a genuinely technical submission, built around pharmaceutical and analytical data rather than legal argument, and manufacturers new to the Kenyan market are well served bringing in regulatory affairs expertise alongside legal counsel at this stage rather than after a first submission has already run into deficiency queries from the Board.
Manufacturing Premises Licensing
Separately from product registration, the premises where the medicine is actually manufactured needs its own licence under the Pharmacy and Poisons Act’s premises registration and licensing regime. Manufacturing a pharmaceutical product in Kenya without carrying on that specific business, without the premises being currently approved for it, is treated the same way the Act treats any other unlicensed pharmacy business, and the penalties that attach to unlicensed premises, up to KES 1,000,000 or up to three years’ imprisonment, apply to a manufacturing site exactly as they would to a distributor’s warehouse.
A manufacturer building or converting a facility in Kenya should sequence premises licensing alongside, not after, the capital investment in plant and equipment, since PPB inspection and approval of the manufacturing site is a precondition the business cannot operate around.
Demonstrating Quality and Manufacturing Standards
Good Manufacturing Practice compliance sits at the centre of both approvals. The PPB assesses a manufacturing site’s practices as part of premises licensing, and continues to inspect against that standard on an ongoing basis rather than treating the initial approval as a one-time hurdle. The Board’s own account of its 2026 activity, including a newly announced inspection regime for the pharmaceutical industry and coordinated product recalls run through the year, is a reasonably clear signal that GMP compliance is actively monitored rather than assumed once a licence is issued.
For a manufacturer, this means the compliance function does not end when the facility opens. Batch records, quality control documentation, and the systems that would support a recall if one were ever required all need to be maintained as a matter of course, not assembled only when an inspector is due.
Local Manufacturing Incentives and Support
Kenya has been actively encouraging local pharmaceutical manufacturing rather than treating new entrants purely as a compliance exercise. The PPB itself reports providing technical guidance to newly established local manufacturers as part of its 2026 reform programme, and manufacturers structuring an investment into local production should also look at the separate incentive regimes available for pharmaceutical manufacturing in Kenya’s Special Economic Zones and Export Processing Zones, which can materially change the tax and duty position of a manufacturing investment compared with operating outside those zones.
Penalties and Enforcement
The consequences for manufacturing or marketing an unregistered product, or operating an unlicensed manufacturing site, mirror the wider penalty structure under the Pharmacy and Poisons Act: unlicensed premises can attract a fine of up to KES 1,000,000 or up to three years’ imprisonment, on top of the commercial cost of product seizure or a recall being forced on the business rather than managed by it.
How We Can Help
Clay & Associates Advocates advises pharmaceutical manufacturers on PPB product registration, manufacturing premises licensing, and structuring local production investment, including through SEZ and EPZ incentive regimes. Our guide to SEZ and EPZ pharmaceutical manufacturing incentives covers the tax and duty side of a local manufacturing investment in detail, and our guide to market entry for foreign pharmaceutical companies is a useful companion for manufacturers also planning direct distribution. Contact our Life Sciences & Healthcare practice to discuss registering a generic product line or licensing a manufacturing facility in Kenya.
Sources: Pharmacy and Poisons Act (Cap. 244), as revised; Pharmacy and Poisons Board, Compendium of Guidelines on Medicines Evaluation and Registration in Kenya; Pharmacy and Poisons Board, Guidelines for Registration and Licensing of Premises; Pharmacy and Poisons Board, PPB Reforms Strengthen Patient Protection (August 2026).
Frequently asked questions
Does registering a generic version of an already-approved medicine skip the PPB approval process?
No. Every product needs its own Market Authorisation regardless of whether the same active ingredient is already registered under another manufacturer’s product. What a generic application does not need to repeat is the full clinical development programme behind the original innovator product, since the submission instead focuses on demonstrating equivalence to the already-registered reference product.
Can I manufacture in a rented facility while my own premises licence is being processed?
The licence attaches to the specific premises being used, so manufacturing at a site that does not itself hold current PPB approval carries the same unlicensed-premises exposure as manufacturing with no licence at all, whether the facility is owned or rented.
Are there tax advantages to manufacturing pharmaceuticals in a Kenyan SEZ or EPZ?
Yes, in general terms. Kenya’s Special Economic Zone and Export Processing Zone regimes offer incentives that can change the tax and duty position of a manufacturing investment, though which regime suits a particular project depends on factors like target market and import content, and is worth structuring with proper advice rather than assumed.
Does GMP compliance only get checked once, when the manufacturing licence is first granted?
No. The PPB continues to inspect licensed manufacturing sites on an ongoing basis, and its own reporting on 2026 enforcement activity, including a newly announced inspection regime for the industry, indicates this is an active and recurring compliance obligation rather than a one-time approval.
